Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...
We tried out Google’s new family of multi-modal models with variants compact enough to work on local devices. They work well.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results